Weight Loss Boost for Postmenopausal Women: Hormone Therapy Enhances Tirzepatide Effectiveness
A recent study led by Mayo Clinic researchers reveals that postmenopausal women undergoing menopausal hormone therapy (MHT) experienced significantly greater weight loss when treated with tirzepatide, a medication approved for weight management. Women receiving both treatments lost, on average, 35% more weight compared to those taking tirzepatide alone. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, offer promising modern avenues for addressing obesity and related health concerns in postmenopausal women.
Menopause, Weight Gain, and Cardiometabolic Risk
Menopause is often associated with weight gain and an increased risk of obesity. These changes contribute to a higher likelihood of developing cardiovascular disease and type 2 diabetes. The decline in estrogen levels during menopause is linked not only to weight gain but also to other physiological changes that can independently elevate cardiovascular risk. “This study provides important insights for developing more effective and personalized strategies for managing cardiometabolic risk in postmenopausal women,” says Regina Castaneda, M.D., postdoctoral research fellow at Mayo Clinic and first author of the study.
Hormone Therapy and Weight Loss Medications: A Synergistic Effect?
Hormone therapy remains the most effective first-line treatment for managing common menopausal symptoms, including hot flashes and night sweats, affecting up to 75% of postmenopausal women. While the interaction between hormone therapy and weight-loss medications has been largely unexplored, previous research suggested that postmenopausal women using hormone therapy may achieve greater weight loss when treated with semaglutide, another GLP-1-based obesity medication.
This new study specifically investigated the impact of hormone therapy on weight loss outcomes with tirzepatide. Researchers analyzed data from 120 adults with overweight or obesity who received tirzepatide for at least 12 months, comparing those who also used hormone therapy with those who did not, while controlling for baseline characteristics.
Study Findings and Considerations
The analysis demonstrated that women receiving both tirzepatide and hormone therapy experienced significantly more weight loss. “In this observational study, women who used menopausal hormone therapy lost about 35% more weight than women taking tirzepatide alone. Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss,” explains Maria Daniela Hurtado Andrade, M.D., Ph.D., endocrinologist at Mayo Clinic and senior author of the study.
Researchers acknowledge that other factors may contribute to these results. It’s possible that women already using hormone therapy were more likely to adopt healthier lifestyles, or that symptom relief from hormone therapy improved sleep and quality of life, facilitating adherence to dietary and physical activity changes.
Potential Mechanisms and Future Research
While further research is needed, the findings suggest a potential synergy between estrogen and GLP-1-based medications like tirzepatide. Dr. Castaneda notes that the observed difference in weight loss warrants further investigation into how these two treatments may interact. “The magnitude of this difference warrants future studies that could help clarify how GLP-1-based obesity medications and menopausal hormone therapy may interact. Interestingly, preclinical data suggest a potential synergy, with estrogen appearing to enhance the appetite-suppressing effects of GLP-1,” says Dr. Castaneda.
Future research will focus on confirming these results in randomized clinical trials and exploring whether the benefits extend beyond weight loss. “Next, we plan to test these observations in a randomized clinical trial and determine if benefits extend beyond weight loss — specifically, whether hormone therapy also enhances the effects of these medications on cardiometabolic measures,” adds Dr. Hurtado Andrade. “If confirmed, this work could speed the development and adoption of new, evidence-based strategies to reduce this risk for millions of postmenopausal women navigating this life stage.”
This research was funded by the Mayo Clinic Center for Women’s Health Research.